Transcatheter Aortic Valve Replacement versus Sutureless Aortic Valve Replacement: A Single Center Retrospective Cohort Study

Young Hak Chung1*, Seung Hyun Lee3*, Young-Guk Ko1, Sak Lee3, Chi-Young Shim1, Chul-Min Ahn1, Geu-Ru Hong1, Jae-Kwang Shim3, Young-Lan Kwak3, and Myeong-Ki Hong1

1Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul; Departments of 2Thoracic and Cardiovascular Surgery and 3Anesthesiology and Pain Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea.

Purpose: This study sought to compare clinical outcomes between transcatheter aortic valve replacement (TAVR) and sutureless aortic valve replacement (SU-AVR).

Materials and Methods: In total, 320 patients with symptomatic severe aortic stenosis who underwent TAVR (n=254) or SU-AVR (n=66) at Severance Cardiovascular Hospital between July 2011 and September 2019 were included for analysis. Propensity score matching and inverse probability weighted adjustment were performed to adjust for confounding baseline characteristics. Outcomes defined by the Valve Academic Research Consortium-2 in 62 patients pairs were compared.

Results: Device success (79.0% vs. 79.0%, p>0.999) and 30-day mortality (4.8% vs. 0.0%, p=0.244) did not differ between the TAVR and SU-AVR groups. The TAVR group developed more frequent mild or moderate paravalvular leakage (59.7% vs. 8.1%, p<0.001), whereas SU-AVR was associated with higher rates of major or life-threatening bleeding (9.7% vs. 22.6%, p=0.040), acute kidney injury (8.1% vs. 21.0%, p=0.041), and new-onset atrial fibrillation (4.8% vs. 32.3%, p<0.001) at 30 days, along with longer stays in the intensive care unit (ICU) (1.9±1.6 days vs. 5.9±9.2 days, p=0.009) and hospital (7.1±7.9 days vs. 13.1±8.8 days, p<0.001). The TAVR group showed a trend towards a higher 1-year all-cause mortality, compared with the SU-AVR group (7.0% vs 1.7%, p=0.149). Cardiovascular mortality, however, did not differ significantly (1.6% vs 1.7%, p=0.960).

Conclusion: TAVR achieved a similar 1-year survival rate free from cardiovascular mortality as SU-AVR and was associated with a lower incidence of complications, except for paravalvular leakage, and shorter stays in the ICU and hospital.

Key Words: Aortic stenosis, transcatheter aortic valve replacement, sutureless aortic valve replacement, severe aortic stenosis

INTRODUCTION

Aortic stenosis (AS) is the most common degenerative heart valve disease in older adults. Conventional surgical aortic valve replacement (SAVR) has been the gold standard for treating symptomatic severe AS. However, a fair proportion (30%~40%) of AS patients are considered unsuitable or high risk for conventional SAVR because of comorbidities or frailty. With population aging, there has been an increasing demand for less invasive treatment options replacing conventional SAVR. In recent years, transcatheter aortic valve replacement (TAVR) and sutureless aortic valve replacement (SU-AVR) have emerged as alternative treatment options. Randomized controlled trials have shown that TAVR is an effective treatment in inoperable patients and equal or superior to conventional SAVR in high-risk patients in regards to clinical outcomes. Further clinical trials have also demonstrated favorable outcomes for TAVR in
SU-AVR were known to be correlated with risk of morbidity and mortality. After removal of a degenerated and calcified valve, SU-AVR allows for rapid deployment of a valve under direct vision that requires no or minimal suturing. While SU-AVR successfully reduces operation times, there is limited evidence supporting improved clinical outcomes with this surgical technique. Furthermore, few studies have directly compared TAVR versus SU-AVR for severe AS. Therefore, this study sought to compare early and late outcomes of TAVR versus SU-AVR for symptomatic severe AS in a single-center cohort.

MATERIALS AND METHODS

Study design and subjects
In total, 433 patients who underwent aortic valve (AV) replacement were screened, and after exclusion of patients treated for combined coronary artery disease and valvular heart disease, 320 patients with symptomatic severe AS who underwent TAVR (n=254) or SU-AVR (n=66) were included in the current analysis (Fig. 1). Decisions regarding the treatment modality were made by the heart team, a multidisciplinary team of interventional and noninterventional cardiologists, cardiac surgeons, anesthesiologists, and imaging specialists based on clinical assessment of each patient’s daily performance and information acquired from pre-treatment transthoracic echocardiography, transesophageal echocardiography, and cardiac computed tomography. Surgical risk was estimated using the European System for Cardiac Operative Risk Evaluation (EuroSCORE) II. The Institutional Review Board of Yonsei University Severance Hospital approved this study (approval no. 4-2020-0813) and waived the requirements for informed consent for this retrospective analysis.

Transcatheter aortic valve replacement
TAVR was performed either under general anesthesia or local anesthesia combined with sedation. A transfemoral approach was the first-line strategy. However, a transsubclavian or transaortic approach was chosen when the transfemoral approach was considered ineligible. Valves used for TAVR included Core-Valve, Evolut R, Evolut Pro (Medtronic, Minneapolis, MN, USA), Sapien 3 (Edwards Lifesciences, Irvine, CA, USA), and Lotus (Boston Scientific, Marlborough, MA, USA). The choice of device and size thereof was determined by the heart team based on the access route lumen diameter and the morphology and dimensions of the AV and adjacent structures according to the manufacturer’s instructions. Generally, we chose a valve size that allowed for 0%-10% oversizing for balloon expandable valves and 10%-25% oversizing for self-expandable valves. Predilation of the AV was selectively carried out using a balloon catheter with a diameter smaller than the minimum annulus diameter when the AV area was smaller than 0.6 cm² or when the AV was severely calcified. The delivery and deployment of the valve was performed according to the instructions for use provided by the device companies. Postdilation was required when moderate to severe paravalvular leakage (PVL) was noted after valve deployment. After successful deployment of the valve, hemostasis of the access site was achieved using two 6-F ProGlide (Abbott Vascular, Santa Clara, CA, USA) via the preclosure method.

Sutureless aortic valve replacement
The implantation of a sutureless bioprosthesis was considered feasible if the mean aortic annulus diameter was 19 to 27 mm. Valves used for SU-AVR included Perceval (Sorin, Saluggia, Italy; true sutureless type) or Intuity (Edwards Lifesciences, rapid deployment type) valves. We made a transverse aortotomy 3.5 cm above the annulus or 0.5 cm above the sinotubular junction (STJ), approximating the epiaortic fat pad for Perceval valves and a classic aortotomy 1 cm above the STJ for Intuity valves. The diseased AV was completely removed, and aortic annulus calcium was clearly removed. The appropriate valve size was selected using the manufacturer sizing tool. Three 4/0 polypropylene guiding sutures were placed at the nadir point of each valve sinus. Simultaneously, an appropriate-size prosthesis was collapsed on a separate table and fixed into the manufacturer holder. Three guiding sutures were passed through the three eyelets at the inflow ring of the prosthesis, which was consequently positioned into the aortic annulus. The AV was released, and the holder was removed. The prosthesis was dilated with a balloon at 4 atmospheres for 30 seconds while the field was rinsed with warm saline. Afterwards, the three guiding sutures were removed, and the aorta was closed using running sutures in a standard fashion.
Follow-up and data collection
All patients who underwent TAVR and SU-AVR were clinically followed at 3- or 6-month intervals after the procedure. Follow-up transthoracic echocardiography was performed within 7 days, at 1 year, and thereafter annually after the AV replacement. Information on mortality, cause of death, and the incidences of myocardial infarction, stroke, permanent pacemaker implantation, major or life-threatening bleeding, hospitalization for heart failure, endocarditis, and valve thrombosis were collected during the follow-up period.

Study endpoints and definitions
The primary end point was defined as 30-day mortality. Secondary end points were 1-year mortality and postoperative complications that may arise following a procedure. Postoperative outcomes were defined based on the Valve Academic Research Consortium-2 definitions.14 Before discharge, transthoracic echocardiography was performed for all patients. PVL with aortic regurgitation was determined based on color Doppler imaging outcomes. All-cause mortality was defined as that involving both cardiovascular and non-cardiovascular mortality. Cardiovascular mortality was defined as death due to proximate cardiac cause (e.g., myocardial infarction, cardiac tamponade, worsening heart failure), death caused by noncoronary vascular conditions (e.g., neurological events, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular disease), all procedure-related deaths (including those related to a complication of the procedure or treatment for a complication of the procedure), all valve-related deaths (including structural or nonstructural valve dysfunction or other valve-related adverse events), sudden or unobserved death, or death from unknown causes. Non-cardiovascular mortality was defined as one wherein the primary cause of death is clearly related to another condition (e.g., infection, trauma, cancer, suicide). 30-day mortality consisted of all-cause mortality within 30 days of the index procedure. 1-year mortality was defined as mortality occurring within 1 year after the index procedure. Device success was defined as the absence of procedural mortality and correct positioning of a single prosthetic heart valve into the proper anatomical location and intended performance of the prosthetic heart valve with absence of prosthesis-patient mismatch, mean AV gradient ≥20 mm Hg or peak velocity ≥3 m/s, or moderate/severe prosthetic valve regurgitation. Life-threatening bleeding was defined as fatal bleeding [Bleeding Academic Research Consortium (BARC) type 5]; bleeding in a critical organ, such as intracranial, intraspinal, intraocular, or pericardial necessitating periarteriendectomy, or intramuscular with compartment syndrome (BARC type 3b and 3c); bleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery (BARC type 3b); overt source of bleeding with drop in hemoglobin ≥5 g/dL or whole blood or packed red blood cells (RBC) transfusion ≥4 units (BARC type 3b). Major bleeding was defined as overt bleeding associated with either a drop in hemoglobin level of at least 3.0 g/dL or requiring transfusion of two or three units of whole blood/RBC, or causing hospitalization or permanent injury, or requiring surgery (BARC type 3a).15 Acute kidney injury (AKI) was defined as an increase in serum creatinine by ≥0.3 mg/dL (≥26.5 micromol/L) within 48 hours, an increase in serum creatinine to ≥1.5 times baseline, or urine volume <0.5 mL/kg/hour for 6 hours.16

Statistical analysis
Statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA) and R package version 4.0.0 (http://www.R-project.org). Continuous data are presented as a mean ± standard deviation, and categorical data are presented as percentages or absolute numbers. The Shapiro-wilk test and Quantile-Quantile Plot were performed before analysis, and the data were confirmed to be normally distributed. Comparisons of continuous variables between patients treated with TAVR and patients treated with SU-AVR were made via the independent t-test, and comparisons of categorical variables were made via the chi-square test (Fisher’s exact test). Propensity score matching (PSM) and inverse probability weighted (IPW) adjustment were performed to adjust for significant differences in baseline characteristics and to reduce the impact of potential confounding factors and selection bias. Propensity scores were calculated in a non-parsimonious way including all preoperative variables [age, sex, body mass index (BMI); history of hypertension, diabetes mellitus, dyslipidemia, chronic kidney disease, end-stage renal disease, smoking, coronary artery disease, previous cardiac surgery, stroke, atrial fibrillation (AF), peripheral artery disease, chronic lung disease and cancer; New York Heart Association classification, EuroSCORE II, AV type, left ventricular ejection fraction, AV area, and mean annulus diameter at baseline]. PSM was performed using the “MatchIt” package in R software. We performed PSM with the caliper set to 0.01 when matching. In the PSM, each patient in the TAVR group was matched to a patient in the SU-AVR group who had the closest propensity score, selected using the greedy algorithm. The analyses performed before the match were performed again after the match. Weights for patients treated with TAVR were the inverse of the propensity score, and weights for patients treated with SU-AVR were the inverse (1–propensity score). Finally, results using IPW adjustment with stabilization and trimming of weights were presented. Weights were set equal to 0.10 if the stabilized weight was less than 0.10 and set equal to 10 if the stabilized weight was greater than 10. Survival curves were compared with a stratified log-rank test for the unmatched, matched pairs, and IPW-adjusted pairs. All tests were two-tailed, and p values <0.05 were considered to indicate statistical significance.

https://doi.org/10.3349/ymj.2021.62.10.885
RESULTS

Baseline clinical characteristics
The baseline clinical characteristics of study subjects are summarized in Table 1 and Supplementary Table 1 (only online). Patients in the TAVR group were older (81.3±5.8 years vs. 75.7±5.4 years, \(p<0.001\)) and had lower BMI (23.2±3.8 vs. 25.0±3.5, \(p<0.001\)), more frequent peripheral artery disease (29.5% vs. 7.6%, \(p<0.001\)), and higher EuroSCORE II (≥4%) (39.8% vs. 13.6%, \(p<0.001\)), compared with those in the SU-AVR group. After PSM, 62 matched patient groups showed no significant differences in baseline clinical variables (Table 1, Fig. 2).

Procedural data
The procedural data are summarized in Table 2. Among a total of 254 patients, 249 (98%) were treated with TAVR via a transfemoral approach, 3 (1.2%) via a transsubclavian approach, and 2 (0.8%) via a transaortic approach. CoreValve (Medtronic), Evolut R (Medtronic), Evolut Pro (Medtronic), Sapien 3 (Edwards Lifesciences), and Lotus (Boston Scientific) valves were used in 64 (25.2%), 101 (39.8%), 17 (6.7%), 61 (24.0%), and 11 (4.3%) patients, respectively. TAVR was performed as an emergent procedure in 7 (2.8%) patients. Among all 254 cases, 228 (89.8%) were performed under general anesthesia and 26 (10.2%) under local anesthesia combined with sedation. SUn

Table 1. Characteristics of TAVR and SU-AVR Patients Before and After Matching

| Characteristics                  | Before matching | \(p\) value | After matching | \(p\) value |
|----------------------------------|----------------|-------------|----------------|-------------|
|                                 | TAVR (n=254)   | SU-AVR (n=66) |                |             |
| Sex                              |                |             |                |             |
| Male                             | 115 (45.3)     | 27 (40.9)   | 0.525          |             |
| Female                           | 139 (54.7)     | 39 (59.1)   |                |             |
| Age (yr)                         | 81.3±5.8       | 75.7±5.4    | \(<0.001\)     |             |
| BMI (kg/m²)                      | 23.2±3.8       | 25.0±3.5    | \(<0.001\)     |             |
| HTN                              | 211 (83.1)     | 55 (83.3)   | 0.960          |             |
| DM                               | 106 (41.7)     | 26 (39.4)   | 0.731          |             |
| Dyslipidemia                     | 175 (68.9)     | 49 (74.2)   | 0.399          |             |
| CKD (stage≥III)                  | 133 (52.4)     | 26 (39.4)   | 0.061          |             |
| ESRD                             | 23 (9.1)       | 5 (7.6)     | 0.705          |             |
| Current smoking                  | 9 (3.5)        | 4 (6.1)     | 0.316          |             |
| CAD                              | 132 (52.0)     | 30 (45.5)   | 0.346          |             |
| Previous cardiac surgery         | 28 (11.0)      | 5 (7.6)     | 0.412          |             |
| Stroke                           | 51 (20.1)      | 16 (24.2)   | 0.459          |             |
| AF                               | 52 (20.5)      | 8 (12.1)    | 0.122          |             |
| PAD                              | 75 (29.5)      | 5 (7.6)     | \(<0.001\)     |             |
| Chronic lung disease             | 44 (17.3)      | 9 (13.6)    | 0.473          |             |
| Active malignancy                | 18 (7.1)       | 2 (3.0)     | 0.389          |             |
| NYHA III/V                       | 155 (61.0)     | 43 (65.2)   | 0.539          |             |
| EuroSCORE II (≥4%)               | 101 (39.8)     | 9 (13.6)    | \(<0.001\)     |             |

AF, atrial fibrillation; BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; DM, diabetes mellitus; ESRD, end-stage renal disease; HTN, hypertension; NYHA, New York Heart Association; PAD, peripheral artery disease; EuroSCORE, European System for Cardiac Operative Risk Evaluation; SU-AVR, sutureless aortic valve replacement; TAVR, transcatheter aortic valve replacement.

Data are expressed as n (%) or mean±standard deviation.
Table 2. Procedural Data of TAVR and SU-AVR Patients Before and After Matching

| Variables                  | TAVR (n=254) | SU-AVR (n=66) | p value | TAVR (n=62) | SU-AVR (n=62) | p value |
|----------------------------|--------------|---------------|---------|--------------|---------------|---------|
| Preprocedural              |              |               |         |              |               |         |
| AV type                    |              |               |         |              |               |         |
| Tricuspid                  | 236 (96.3)   | 57 (91.9)     | 0.139   | 60 (96.8)    | 57 (91.9)     | 0.440   |
| Bicuspid                   | 5 (2.0)      | 4 (6.5)       |         | 2 (3.2)      | 4 (6.5)       |         |
| Bioprosthetic              | 4 (1.6)      | 1 (1.6)       |         | 0 (0.0)      | 1 (1.6)       |         |
| AV area (cm²)              | 0.73±0.18    | 0.72±0.19     | 0.741   | 0.72±0.17    | 0.72±0.19     | 0.901   |
| Annulus diameter (mm)      | 23.2±2.4     | 22.7±2.2      | 0.106   | 22.8±2.7     | 22.6±2.2      | 0.771   |
| Peak PG (mm Hg)            | 82.9±28.2    | 86.6±25.9     | 0.335   | 85.0±28.1    | 88.1±25.4     | 0.519   |
| Mean PG (mm Hg)            | 50.5±18.7    | 53.2±17.4     | 0.296   | 52.9±19.4    | 54.0±17.3     | 0.552   |
| LVEF (%)                   | 61.3±14.9    | 60.7±13.9     | 0.762   | 62.2±14.6    | 60.8±13.8     | 0.605   |
| TAVR valve type            |              |               |         |              |               |         |
| CoreValve                  | 64 (25.2)    | 16 (25.8)     |         |              |               |         |
| Evolut R                   | 101 (39.8)   | 25 (40.3)     |         |              |               |         |
| Evolut Pro                 | 17 (6.7)     | 3 (4.8)       |         |              |               |         |
| Sapien 3                   | 61 (24.0)    | 15 (24.2)     |         |              |               |         |
| Lotus                      | 11 (4.3)     | 3 (4.8)       |         |              |               |         |
| TAVR valve diameter (mm)   | 25.1±2.3     | 23.8±2.2      |         |              |               |         |
| Access route               |              |               |         |              |               |         |
| Transfemoral               | 249 (98.0)   | 62 (100)      |         |              |               |         |
| Transsubclavian            | 3 (1.2)      | 0 (0.0)       |         |              |               |         |
| Transaortic                | 2 (0.8)      | 0 (0.0)       |         |              |               |         |
| SU-AVR prosthesis          |              |               |         |              |               |         |
| Perceval                   | 64 (97.0)    | 60 (96.8)     |         |              |               |         |
| Intuity                    | 2 (3.0)      | 2 (3.2)       |         |              |               |         |
| Pre-dilation               | 158 (62.2)   | 40 (64.5)     |         |              |               |         |
| Post-dilation              | 94 (37.0)    | 26 (41.9)     |         |              |               |         |
| ACC time (min)             | 40.1±13.9    | 39.9±14.2     |         |              |               |         |
| CPB time (min)             | 72.3±24.2    | 72.6±24.8     |         |              |               |         |

ACC, aortic cross-clamp; AV, aortic valve; CPB, cardiopulmonary bypass; LVEF, left ventricular ejection fraction; PG, pressure gradient; SU-AVR, sutureless aortic valve replacement; TAVR, transcatheter aortic valve replacement.

Data are expressed as n (%) or mean±standard deviation.

AVR was performed using two types of prostheses: Perceval S (Sorin) was implanted in 64 (97.0%), and Intuity (Edwards Lifesciences) was used in 2 (3.0%). SU-AVR was performed as an emergent surgery in 2 (3.0%). The mean CPB time was 72.3±24.2 minutes, and the mean ACC time was 40.1±13.9 minutes.

Early outcomes at 30 days
The early outcomes of TAVR and SU-AVR are presented in Table 3, Supplementary Table 2 (only online), and Supplementary Table 3 (only online), Fig. 3. The device success did not differ significantly between the two groups (79.0% vs. 79.0%, p=0.999). There was no significant difference in 30-day mortality between the TAVR and SU-AVR groups before PSM (4.7% vs. 1.5%, p=0.481). However, there was a trend toward a higher 30-day mortality with TAVR after PSM (4.8% vs. 0.0%, p=0.244).

From a hemodynamic standpoint, the incidence of any mild or moderate PVL was higher in the TAVR group than in the SU-AVR group (59.7% vs. 8.1%, p<0.001). However, there was no significant difference between the two groups in the incidence of moderate PVL (1.6% vs. 0.0%, p=0.999). There was no case of severe PVL in either patient group. The TAVR group showed significantly lower transaortic mean and peak gradients (11.2±5.7 mm Hg vs. 14.7±3.8 mm Hg, p<0.001 and 27.5±7.0 mm Hg vs. 21.4±10.5 mm Hg, p<0.001, respectively), but larger AV areas (1.8±0.4 cm² vs. 1.6±0.4 cm², p=0.009). Major or life-threatening bleeding (9.7% vs. 22.6%, p=0.040), AKI (8.1% vs. 21.0%, p=0.041), and new-onset AF (4.8% vs. 32.3%, p<0.001) were less frequent in the TAVR group than in the SU-AVR group. Furthermore, hospital stay from procedure to discharge (7.1±7.9 days vs. 13.1±8.8 days, p<0.001) and intensive care unit (ICU) stay (1.9±1.6 days vs. 5.9±9.2 days, p=0.009) were shorter in the TAVR group than in the SU-AVR group. However, there was a trend towards a higher incidence of permanent pacemaker implantation in the TAVR group (14.5% vs. 6.5%, p=0.143).

https://doi.org/10.3349/ymj.2021.62.10.885
Clinical outcomes at 1-year follow-up

Patients were followed for a median duration of 12.9 (interquartile range: 4.1–26.5) months. The clinical outcomes during the follow-up are presented in Table 4 and Supplementary Table 4 (only online), Figs. 3 and 4. Before PSM, there was a trend toward a higher all-cause mortality in the TAVR group than in the SU-AVR group (11.2% vs. 3.1%, \( p = 0.068 \)). Among the 24 patients who died in the TAVR group during the follow-up period, 11 (45.8%) died due to sepsis, 3 (12.5%) died due to the progression or worsening of an underlying disease, 3 (12.5%) died due to gastrointestinal bleeding, 3 (12.5%) died due to respiratory failure caused by an aspiration, and 4 (16.7%) died due to traumatic subdural hemorrhage. In the SU-AVR group, two patients died during follow up: one died due to respiratory failure caused by aspiration, and another patient died due to sepsis. However, cardiovascular mortality did not differ between the TAVR group and the SU-AVR group (1.6% vs. 1.7%, \( p = 0.960 \)). Major or life-threatening bleeding was significantly lower in the TAVR group than in the SU-AVR group (10.9% vs. 25.8%, \( p = 0.023 \)). However, there were no significant differences between the two groups in the incidences of myocardial infarction, stroke, permanent pacemaker implantation, hospitalization for heart failure, endocarditis, and valve thrombosis.

DISCUSSION

In this retrospective single cohort study, TAVR and SU-AVR showed no significant differences in 30-day and 1-year mortality rates after adjustment for confounding factors using PSM and IPW adjustment. SU-AVR showed higher incidences of major or life-threatening bleeding, AKI, and new-onset AF compared with TAVR, whereas TAVR was associated with a higher incidence of PVL and a trend towards a higher risk of permanent pacemaker implantation.
Fig. 3. Clinical outcomes according to procedure. Impact on clinical outcomes of the two procedures at 30-day or 1-year follow up. TAVR was associated with increased PVL, whereas SU-AVR was associated with increased major or life threatening bleeding, AKI, and new-onset AF. AF, atrial fibrillation; AKI, acute kidney injury; AV, atrioventricular; CL, confidence limit; HF, heart failure; LBBB, left bundle branch block; LCL, lower confidence limit; OR, odds ratio; PM, pacemaker; PVL, paravalvular leakage; SU-AVR, sutureless aortic valve replacement; TAVR, transcatheter aortic valve replacement; UCL, upper confidence limit.

Recently, a meta-analysis of seven randomized controlled clinical trials demonstrated that TAVR was associated with a reduction in all-cause mortality and stroke up to 2 years, irrespective of the baseline surgical risk and type of transcatheter heart valve system, compared with conventional SAVR. Furthermore, patients treated with TAVR experienced a reduction in the risk of new-onset AF, AKI, and major bleeding. Sutureless valves offer faster implantation with significantly reduced CPB and ACC times, compared with conventional SAVR, and the absence of a sewing ring may also result in improved hemodynamics. A network meta-analysis of 16432 patients from seven randomized controlled trials and 25 propensity score-

Table 4. Clinical Outcomes at 1 Year: TAVR and SU-AVR Before and After Matching

| Variables                          | Before matching | After matching | p value | Before matching | After matching | p value |
|------------------------------------|-----------------|----------------|---------|-----------------|----------------|---------|
| All-cause mortality                | TAVR (n=254)    | SU-AVR (n=66)  | 0.068   | TAVR (n=62)     | SU-AVR (n=62)  | 0.149   |
| Cardiovascular mortality           | 6 (2.4)         | 1 (1.6)        | 0.656   | 1 (1.6)         | 1 (1.7)        | 0.960   |
| Myocardial infarction              | 1 (0.4)         | 0 (0)          | 0.010   | 0 (0)           | 0 (0)          | >0.999  |
| Stroke                             | 12 (5.0)        | 5 (7.9)        | 0.400   | 2 (3.2)         | 5 (8.3)        | 0.270   |
| Permanent PM implantation          | 34 (14.1)       | 7 (11.1)       | 0.488   | 9 (14.5)        | 7 (11.7)       | 0.544   |
| Major or life-threatening bleeding | 22 (9.6)        | 17 (25.8)      | <0.001  | 6 (10.9)        | 16 (25.8)      | 0.023   |
| Hospitalization for HF             | 13 (6.4)        | 2 (3.1)        | 0.356   | 3 (5.1)         | 2 (3.3)        | 0.584   |
| Endocarditis                       | 1 (0.6)         | 1 (1.7)        | 0.385   | 0 (0)           | 1 (1.8)        | 0.344   |
| Valve thrombosis                   | 1 (0.6)         | 2 (4.4)        | 0.101   | 0 (0)           | 2 (4.8)        | 0.179   |
| Hemodynamic results                |                 |                |         |                 |                |         |
|AVA (cm²)                           | 1.8±0.4         | 1.5±0.3        | 0.021   | 1.7±0.4         | 1.5±0.3        | 0.218   |
|Peak gradient (mm Hg)               | 19.8±8.8        | 23.2±8.9       | 0.019   | 23.6±11.8       | 23.8±8.8       | 0.912   |
|Mean gradient (mm Hg)               | 10.1±4.6        | 12.1±5.3       | 0.011   | 12.1±6.1        | 12.4±5.3       | 0.788   |

AVA, aortic valve area; HF, heart failure; PM, pacemaker; SU-AVR, sutureless aortic valve replacement; TAVR, transcatheter aortic valve replacement. Data are expressed as n (%) or mean±standard deviation.

https://doi.org/10.3349/ymj.2021.62.10.885
matched studies found that SU-AVR was associated with less major bleeding and AKI than conventional SAVR. However, according to another study, SU-AVR showed higher incidences of PVL and permanent pacemaker implantation than conventional SAVR. To date, there have been no randomized controlled trials comparing TAVR and SU-AVR. Thus, the current clinical evidence is based only on observational cohort studies or meta-analyses. Several meta-analyses reported higher post-procedural or 30-day mortality rates with TAVR group than with SU-AVR. Similarly, in the present study, the TAVR group showed a trend towards a higher 30-day mortality than the SU-AVR group. However, there was no difference in cardiovascular mortality. Thus, the potentially higher mortality in the TAVR group may be explained by non-cardiovascular causes due to relatively older age and higher surgical risk profile expressed as in EuroSCORE II, although these differences were not statistically significant.

In this study, the incidence of mild or moderate PVL was higher for TAVR than SU-AVR, although the incidence of moderate PVL alone showed no difference between the two groups.

**Fig. 4.** Cumulative Kaplan-Meier estimates of (A) overall, (B) propensity score matched, and (C) IPW all-cause mortality and cardiovascular mortality between TAVR and SU-AVR groups during the 1-year follow-up period. Cardiovascular mortality did not differ between the TAVR and SU-AVR groups. IPW, inverse probability weighted; SU-AVR, sutureless aortic valve replacement; TAVR: transcatheter aortic valve replacement.
There was no case of severe PVL in the TAVR group. These results are in line with the results of previously published studies. 16,22 It has been shown that the presence of PVL is a predictor of lower survival. 21 The surgical approach has an advantage of reducing the risk of PVL by removal of calcified AV tissues. However, adoption of a new generation TAVR device that was specially designed to improve sealing between the aortic annulus and the TAVR valve has greatly reduced the incidence of significant PVL after TAVR. 24,25 In the present study, TAVR demonstrated reduced incidences of major or life-threatening bleeding and AKI. These findings are also consistent with previous studies. 17 Postoperative new-onset AF occurred in about 30% of the patients treated with SU-AVR in our cohort, which is also compatible with other studies reporting AF incidences ranging from 16.7% to 41%. 26,27 Multiple acute transient factors, such as an increase in the circulating catecholamines, heightened sympathetic and parasympathetic tone, atrial stretch, transcellular fluid and electrolyte shifts, metabolic abnormalities, inflammation, and pericarditis, contribute to AF after cardiac surgery. 28 TAVR showed shorter durations of hospitalization and ICU stay compared to SU-AVR owing to the less invasive nature and lack of extracorporeal circulation. However, the length of hospital or ICU stay can differ between centers due to differences in the policies of each center or clinician, regardless of each patient’s postoperative course.

Previous studies reported no significant differences between SU-AVR and TAVR in terms of the incidence of atioventricular block and permanent pacemaker implantation. 22,28 Similarly, in our study, there was no statistically significant difference between the two groups, although compared to patients treated with SU-AVR, there was a trend toward a higher risk of permanent pacemaker implantation in patients treated with TAVR. There is wide variability in terms of the postoperative need for pacemaker implantation among different TAVR devices because, with some prostheses, the incidence of pacemaker implantation is as high as 28% and the rate of new or worsened left bundle branch block is 78%. 29 SU-AVR or conventional SAVR may be a better choice for treatment of patients with anatomy precluding a good outcome from TAVR (e.g., short distance between coronary ostia and AV annulus, bicuspid AV, asymmetric calcification), concomitant conditions warranting surgery (e.g., aortic root aneurysm, complex coronary artery disease, severe mitral or tricuspid valve disease), inadequate vascular access condition, or active infective endocarditis. SU-AVR may be preferred to conventional SAVR in cases where shortening of CPB and ACC times are of great clinical importance. Therefore, a multidisciplinary heart team needs to evaluate the conditions of the patients and to guide the most appropriate treatment for each individual patient.

There are some limitations to this study. First, this study was conducted as a single-center retrospective analysis with a relatively small study population. We aimed to minimize selection bias using PSM. However, confounding factors may not have been sufficiently controlled as they would have been in a randomized controlled trial. Second, the follow-up duration was limited to assess the impact of the procedures on late clinical outcomes. Third, the impact of different TAVR or surgical valve types, valve sizes, and detailed native AV anatomy factors on the clinical outcomes could not be evaluated in this study due to the small study size.

In conclusion, TAVR was associated with increased PVL, whereas SU-AVR was associated with increased major or life-threatening bleeding, AKI, and new-onset AF, compared to TAVR, in this study. Therefore, compared to SU-AVR, TAVR appears to be a safer procedure for the treatment of patients with symptomatic severe AS.

ACKNOWLEDGEMENTS

This research was supported by a fund from the Cardiovascular Research Center, Seoul, Korea.

AUTHOR CONTRIBUTIONS

Conceptualization: Young Hak Chung, Seung Hyun Lee, and Young-Guk Ko. Data curation: Young Hak Chung, Seung Hyun Lee, Young-Guk Ko, Sak Lee, Chi-Young Shim, Chul-Min Ahn, Geu-Ru Hong, and Myeong-Ki Hong. Formal analysis: Young Hak Chung, Seung Hyun Lee, and Young-Guk Ko. Funding acquisition: Young-Guk Ko. Investigation: Young Hak Chung, Seung Hyun Lee, and Young-Guk Ko. Methodology: Young Hak Chung, Seung Hyun Lee, and Young-Guk Ko. Project administration: all authors. Resources: all authors. Software: Young Hak Chung, Seung Hyun Lee, and Young-Guk Ko. Supervision: Sak Lee, Chi-Young Shim, Chul-Min Ahn, Geu-Ru Hong, and Myeong-Ki Hong. Validation: Sak Lee, Chi-Young Shim, Chul-Min Ahn, Geu-Ru Hong, and Myeong-Ki Hong. Visualization: Young Hak Chung, Seung Hyun Lee, and Young-Guk Ko. Writing—original draft: Young Hak Chung, Seung Hyun Lee, and Young-Guk Ko. Writing—review & editing: Young-Guk Ko. Approval of final manuscript: all authors.

ORCID iDs

Young Hak Chung https://orcid.org/0000-0003-3115-5585
Seung Hyun Lee https://orcid.org/0000-0002-0311-6565
Young-Guk Ko https://orcid.org/0000-0001-7748-5788
Sak Lee https://orcid.org/0000-0001-6130-2342
Chi-Young Shim https://orcid.org/0000-0002-6136-0136
Chul-Min Ahn https://orcid.org/0000-0002-7071-4370
Geu-Ru Hong https://orcid.org/0000-0003-4981-3304
Jae-Kwang Shim https://orcid.org/0000-0001-9093-9692
Young-Lan Kwak https://orcid.org/0000-0002-2984-9927
Myeong-Ki Hong https://orcid.org/0000-0002-2090-2031

REFERENCES

1. Danielsen R, Aspelund T, Harris TB, Gudnason V. The prevalence of aortic stenosis in the elderly in Iceland and predictions for the coming decades: the AGES-Reykjavik study. Int J Cardiol 2014;176: 916-22.
2. Brennan JM, Edwards FH, Zhao Y, O’Brien SM, Douglas PS, Pe-
terson ED. Long-term survival after aortic valve replacement among high-risk elderly patients in the United States: insights from the Society of Thoracic Surgeons Adult Cardiac Surgery Database, 1991 to 2007. Circulation 2012;126:1621-9.

3. Jung B, Cachier A, Baron G, Messuka-Zeitoun D, Delahaye F, Tornos P, et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J 2005;26:2714-20.

4. Bilkhu R, Borger MA, Briffa NP, Jhanahiri M. Sutureless aortic valve prostheses. Heart 2019;105:s16-20.

5. Ellison M, Maze A, Carrier M, Bouchard D. Sutureless and transcatheter aortic valve replacement: when rivals become allies. Semin Thorac Cardiovasc Surg 2019;32:427-30.

6. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011;364:2187-98.

7. Adams DH, Poppma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 2014;370:1790-8.

8. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016;374:1609-20.

9. Reardon MJ, Van Mieghem NM, Poppma JJ, Kleiman NS, Sondergaard L, Muntz M, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 2017;376:1321-31.

10. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 2019;380:1695-705.

11. Gillmanov D, Miceli A, Bevilacqua S, Farnetti P, Solinas M, Ferrari M, et al. Sutureless implantation of the perceval s aortic valve prosthesis through right anterior minithoracotomy. Ann Thorac Surg 2013;96:2101-8.

12. Powell R, Pelletier MP, Chu MWA, Bouchard D, Melvin KN, Adams C. The percutal sutureless aortic valve: review of outcomes, complications, and future direction. Innovations (Philad) 2017;12:155-73.

13. Wang N, Tsai YC, Niles N, Tchantchaleishvili V, Di Eusanio M, Yan NG, et al. Transcatheter aortic valve implantation (TAVI) versus sutureless aortic valve replacement (SU-AVR) for aortic stenosis: a systematic review and meta-analysis of matched studies. J Thorac Dis 2016;8:3283-93.

14. Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone EH, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). Eur J Cardiothorac Surg 2012;42:S45-60.

15. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011;123:2736-47.

16. Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdman EA, Goldstein SL, et al. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012;2:1-138.

17. Siontis GCM, Overchouk P, Cahill TJ, Modine T, Prendergast B, Praz F, et al. Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis. Eur Heart J 2019;40:3143-53.

18. Lloyd D, Luc JGY, Indja BE, Leung W, Wang N, Phan K. Transcatheter, sutureless and conventional aortic-valve replacement: a network meta-analysis of 16,432 patients. J Thorac Dis 2019;11:188-99.

19. Sohn SH, Jang MJ, Hwang HY, Kim KH. Rapid deployment or sutureless versus conventional bioprosthetic aortic valve replacement: a meta-analysis. J Thorac Cardiovasc Surg 2018;155:2402-12.e5.

20. Meco M, Miceli A, Montisci A, Donatelli F, Cirri S, Ferrari M, et al. Sutureless aortic valve replacement versus transcatheter aortic valve implantation: a meta-analysis of comparative matched studies using propensity score matching. Interact Cardiovasc Thorac Surg 2018;26:202-9.

21. Shinn SH, Altarabsheh SE, Deo SV, Sabik JH, Markowitz AH, Park SJ. A systemic review and meta-analysis of sutureless aortic valve replacement versus transcatheter aortic valve implantation. Ann Thorac Surg 2018;106:924-9.

22. Santarpino G, Pfeiffer S, Jessl D, Dell’Aquila AM, Pollari F, Pauschinger M, et al. Sutureless replacement versus transcatheter valve implantation in aortic valve stenosis: a propensity-matched analysis of 2 strategies in high-risk patients. J Thorac Cardiovasc Surg 2014;147:561-7.

23. Vasa-Nicocera M, Sinning JM, Chin D, Lim TK, Spyt T, Jilaihawi H, et al. Impact of paravalvular leakage on outcome in patients after transcatheter aortic valve implantation. JACC Cardiovasc Interv 2012;5:858-65.

24. Hussner O, Pellegrini C, Kessler T, Burgdorf C, Thaller H, Mayr NP, et al. Outcomes after transcatheter aortic valve replacement using a novel balloon-expandable transcatheter heart valve: a single-center experience. JACC Cardiovasc Interv 2015;8:1809-16.

25. Forrest JK, Mangi AA, Poppma JJ, Khbabez K, Reardon MJ, Kleiman NS, et al. Early outcomes with the Evolut PRO repositionable self-expanding transcatheter aortic valve with pericardial wrap. JACC Cardiovasc Interv 2018;11:160-8.

26. van Boxtel AG, Houthuijzen P, Hamad MA, Sjatskig J, Tan E, Prizen FW, et al. Postoperative conduction disorders after implantation of the self-expandable sutureless Perceval S bioprosthesis. J Heart Valve Dis 2014;23:319-24.

27. Mazine A, Teoh K, Bouhout I, Bhatnagar G, Pelletier M, Voisine P, et al. Decision-making in elderly patients with severe aortic stenosis: a systematic review and meta-analysis of matched studies using propensity score matching. Interact Cardiovasc Thorac Surg 2019;32:427-30.